Novartis Organizes Tokyo Forum For Diabetes Drug Equa
This article was originally published in PharmAsia News
Executive Summary
Following labeling changes that allow longer dosing periods for Novartis AG's Equa (vidagliptin), Japanese physicians reported that the drug's glucose-lowering effect has made the drug a first-choice treatment for type 2 diabetes, said Yukiko Onishi, director of Clinical Trials at Institute for Adult Diseases, Asahi Life Foundation
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.